These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 15947852)
1. Dapsone syndrome with acute renal failure during leprosy treatment: case report. Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852 [TBL] [Abstract][Full Text] [Related]
2. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy. Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479 [TBL] [Abstract][Full Text] [Related]
4. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia. Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737 [TBL] [Abstract][Full Text] [Related]
6. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. Sapkota BR; Shrestha K; Pandey B; Walker SL Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989 [TBL] [Abstract][Full Text] [Related]
7. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore. Lim JT; Tan T Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116 [TBL] [Abstract][Full Text] [Related]
9. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT. Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643 [TBL] [Abstract][Full Text] [Related]
10. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. Deps P; Guerra P; Nasser S; Simon M Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach. Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240 [TBL] [Abstract][Full Text] [Related]
12. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. Sheen YS; Chu CY; Wang SH; Tsai TF J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390 [TBL] [Abstract][Full Text] [Related]
14. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally. Lockwood DN; Cunha Mda G Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024 [No Abstract] [Full Text] [Related]
15. Adverse effects from multi-drug therapy in leprosy: a Brazilian study. Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772 [TBL] [Abstract][Full Text] [Related]